Status:
COMPLETED
A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Arthropathy of Hip
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A single preoperative dose of tranexamic acid (TXA) reduces blood loss and red blood cell transfusion in primary hip arthroplasty. Numerous regimens have been tested, ranging from 10mg/kg up to 3g. Ho...
Detailed Description
This dose-response study is a randomized double blind study with five groups of 30 patients each. Patients will be randomized to placebo, tranexamic acid (TXA) 300 mg, tranexamic acid (TXA) 500 mg, tr...
Eligibility Criteria
Inclusion
- Patient requiring primary hip arthroplasty (less than 3 months)
- Informed Consent from the patient or their legally authorized representative
- Affiliation to French Social Security Healthcare system
Exclusion
- Hip fracture of less than 3 months
- Bilateral hip arthroplasty or anterior approach to hip arthroplasty
- Haemorrhagic surgery in the previous 2 weeks
- Contraindication to tranexamic acid
- Contraindication to apixaban
- Chronic use of anticoagulant
- Pregnancy
- Previous participation to this study
Key Trial Info
Start Date :
December 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03822793
Start Date
December 7 2023
End Date
July 11 2025
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint-Etienne
Saint-Etienne, France